
Oramed Refines Portfolio Strategy as Russell Index Inclusion Looms
Oramed Pharmaceuticals is moving to broaden its investor profile, with the company slated to join the Russell 2000 and 3000 indexes on June 29. The transition follows a series of strategic maneuvers that have left the firm with approximately $270 million in total cash and assets as of the first quarter.



























